Clinical trials: Advanced Esophageal Cancer
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
This pilot clinical trial studies cyclodextrin-based nanopharmaceutical CRLX101 in treating patients with advanced or metastatic stomach, gastroesophageal, or esophageal cancer that has progressed through at least one prior…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT01612546
- Testing
- cyclodextrin-based polymer-camptothecin CRLX101, Laboratory biomarker analysis, Pharmacological studies
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy
Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma
This is one randomized, double-blind, multi-center, placebo-controlled phase III study. The objective of this study is to compare the effectiveness and safety of JS001 combined with paclitaxel and cisplatin(TP regimen )with…
- Trial name
- JUPITER06 (NCT03829969)
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 514 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Esophageal Cancer, Nimotuzumab
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
Patients diagnosed with locally advanced esophageal squamous cell carcinoma (ESCC) who failed to induction chemo(immuno)therapy had poor prognosis. Radiotherpy was an important and effective treatment in treating ESCC.
- Conditions
- Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy
- Trial name
- NCT06410651
- Testing
- Nimotuzumab with chemoradiotherapy
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Squamous Cell Carcinoma, Immunotherapy
Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC.
Conduct a retrospective and prospective study to confirm the association between blood cells counts and the efficacy and safety in immunochemotherapy in patients with advanced esophageal cancer.
- Conditions
- Esophageal Squamous Cell Carcinoma, Immunotherapy, Chemotherapy
- Trial name
- NCT06125262
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangdong Provincial People's Hospital
Stage III Esophageal Squamous Cell Carcinoma
Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC
Esophageal squamous cell carcinoma (ESCC) is one of the ten leading cancers in Taiwanese male. The prognosis is poor with a five-year overall survival rate of 10 to 30 %.
- Trial name
- NCT02812641
- Testing
- BPF-CCRT (run-in), BPF-CCRT (randomized), PF-CCRT (randomized)
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Gastric Cancer
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
This study is a phase III, multi-centre study of olaparib in combination with paclitaxel, compared with placebo in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line…
- Trial name
- NCT01924533
- Testing
- Olaparib, Paclitaxel
- Where
- 57 sites in China, Japan and 2 more
- Volunteers
- 525 people
- Sponsor
- AstraZeneca
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects with Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT04086758
- Testing
- zolbetuximab
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma China, Inc.
ESCC
Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer
Esophageal cancer is one of the most common malignancies, and concurrent chemoradiotherapy (CRT) is the standard treatment for unresectable, locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT07015489
- Testing
- induction chemotherapy and immunotherapy
- Where
- China
- Volunteers
- 44 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Esophageal Squamous Cell Carcinoma, Efficacy
Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma
This is an open-label, randomized, controlled phase II study evaluating induction immuno-chemotherapy and concurrent chemoradiotherapy with or without apatinib in unresectable, locally advanced esophageal squamous cell carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma, Efficacy, Toxicity
- Trial name
- NCT06281886
- Testing
- Induction Immunotherapy-Toripalimab, Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin, Radiotherapy
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Pancreas Cancer
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.
- Conditions
- Breast Cancer, Pancreas Cancer, Prostate Cancer, Lung Cancer
- Trial name
- NCT03199586
- Testing
- NP-G2-044
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Novita Pharmaceuticals, Inc.
Small Cell Carcinoma of Esophagus, Advanced Cancer
Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy
To evaluate the anti-tumor activity, safety and tolerance of toripalimab as monotherapy for patients with small cell esophageal cancer (SCCE), and to explore the potential biomarkers for this treatment.
- Trial name
- NCT03811379
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-sen University
Esophageal Cancer
Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00445861
- Testing
- cetuximab + docetaxel + cisplatin, Treatment level 1, Treatment level 2
- Where
- 2 sites in Switzerland
- Volunteers
- 27 people
- Sponsor
- Swiss Cancer Institute
Esophageal Cancer
Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00354679
- Testing
- bevacizumab, cisplatin, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma, Liver Cirrhosis
Liver and Spleen Stiffness to Predict the Presence of Esaphageal Varices in Cirrhotic With Advanced HCC
Elasto-HCC is a prospective, uncontrolled, multicenter observational study involving several hepatology centers in Italy. Patients with liver cirrhosis and advanced hepatocellular carcinoma (HCC) who will need to undergo systemic…
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Portal Hypertension
- Trial name
- ELASTO-HCC (NCT06773260)
- Testing
- Liver and Spleen stiffness measurement.
- Where
- 12 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Azienda Ospedaliero Universitaria Policlinico Modena
Advanced Esophagus Cancer
Apatinib as First -Line Treatment for Advanced Esophagus Cancer
An Exploratory study of Amapinib for patients with advanced esophagus cancer .
- Trial name
- NCT03542422
- Testing
- Apatinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
Esophagus Cancer
The Efficacy and Safety of Caffeic Acid for Esophageal Cancer
Caffeic acid can target inhibit GASC1 (gene amplified in squamous cell carcinoma 1, also known as KDM4C and JMJD2C) expression and GASC1 is confirmed to be a new oncogene in several cancers including esophageal cancer.
- Trial name
- CAEC (NCT03070262)
- Testing
- CA
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory…
- Conditions
- Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT07284186
- Testing
- PLX-61639
- Where
- 10 sites in United States
- Volunteers
- 155 people
- Sponsor
- Plexium, Inc.
Gastric Cancer
Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer
The purpose of this study is to determine which Arm (capecitabine + irinotecan versus capecitabine + cisplatin) shows higher response rates in the treatment of advanced gastric-oesophagal cancer Furthermore, comparison of…
- Trial name
- NCT00675194
- Testing
- Cisplatin, Irinotecan, Capecitabine
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Johannes Gutenberg University Mainz
Advanced Solid Tumors, Metastatic Solid Tumors
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
- Trial name
- NCT03854227
- Testing
- PF-06939999 dose escalation, PF-06939999 monotherapy, PF-06939999 in combination with docetaxel
- Where
- 22 sites in United States
- Volunteers
- 54 people
- Sponsor
- Pfizer
Esophageal Squamous Cell Carcinoma, Chemoradiotherapy
Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma
Chemoradiotherapy has been a standard modality for inoperable locally advance esophageal carcinoma. The goal of this randomized control study is to compare the feasibility, and survival benefits of whole-course immunonutrition…
- Conditions
- Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Immunonutrition, Inoperable
- Trial name
- NCT05833594
- Testing
- Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Anhui Provincial Hospital